• The European Medicines Agency has granted iptacopan a priority medicines (PRIME) designation in C3 glomerulopathy (C3G). 
  • PRIME is granted for medicines that may offer major therapeutic advance or benefit patients without treatment options.
  • C3 glomerulopathy (C3G) is a rare renal disease, affecting young patients with a poor prognosis and significant unmet need.1